Global Lipid Nanoparticles (LNPs) CDMO Market

Report ID : 1432 | Published : 2022-11-02 | Pages: 170 | Format: PDF/EXCEL

The Global Lipid Nanoparticles (LNPs) CDMO market size is expected to grow at a compound annual growth rate (CAGR) of 13.8% from 2022 to 2030. In recent years, a remarkable advancement in nanoscale drug delivery methods has been made. A novel nano-colloidal system for drug administration has emerged in the form of solid lipid nanoparticles (SLNs). Due to the lipid matrix's biocompatibility, lipid nanoparticles (LNPs) are frequently used in drug delivery. The most promising method for oral delivery is solid lipid nanoparticles (SLN), which have improved solubility, stability, permeability, and bioavailability while posing fewer side effects than standard dose formulations. Increasing clinical demand for small molecules is favouring the business of contract manufacturing service providers.

The most advanced non-viral therapeutically authorised mRNA delivery technologies are lipid nanoparticles (LNPs). The ability of an mRNA vaccine to deliver a therapeutic outcome is related to the capacity of LNPs to provide the nucleic acid intact into cells. For Instance, in 2021,  WACKER and CordenPharma signed a development collaboration in the field of Lipid Nanoparticle formulation. The two companies reported that they intend to jointly develop know-how and methods for manufacturing Lipid Nanoparticles (LNPs) to meet the growing market demand.

Major driving factors of the Lipid Nanoparticles (LNPs) CDMO market are the surging medical applications of nanoparticles, increasing investments by key players in lipid nanoparticles to develop promising drug therapies, rising cases of chronic diseases, an increasing aging population, and a growing number of health-conscious people. The rising chronic and infectious disease cases have increased pharmaceutical companies' product manufacturing burden. Hence, biopharma companies started to opt for contract manufacturing services to save time and handle lipid/nanoparticle production operations, which is expected to create business growth opportunities for the market over the forecast years. However, the high cost of outsourced services, lack of necessary infrastructures, need for specialized expertise for nanoparticle production, and complex manufacturing procedures may restrain the market growth during the estimated timeframe.

The Lipid Nanoparticles (LNPs) CDMO market is segmented based on product, the scale of operation, end-users, and region. The product segment comprises mRNA , Plasmid DNA (pDNA), siRNA, saRNA, microRNA, and Others. By scale of operation, the market is classified into preclinical scale operations, clinical scale operations, and commercial-scale operations. The market is grouped into Pharmaceutical Companies, Academic Research Institute, and Diagnostic Laboratories. Pharmaceutical companies are projected to hold a significant market share over the forecast years owing to the high prevalence of chronic diseases and rising innovative drug developments. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

North America is estimated to witness rapid growth in the next few years due to the increasing awareness about the applications of nanoparticles, rising government investments in the R&D of nanoparticle products, and the high prevalence of chronic diseases.

Some of the key players operating in the Lipid Nanoparticles (LNPs) CDMO market are Corden Pharma GmbH, eTheRNA, Curapath (Polypeptide Therapeutic Solutions (PTS)), FUJIFILM Corporation, ST Pharm Co Ltd, Exelead (Merck KGaA) , Avanti Polar Lipids, Inc. (Croda International Plc.), Emergent CDMO, Esco Aster Pte Ltd, Vernal Biosciences, Arranta Bio, Phosphorex Inc, Ardena Holding NV, Curia Global, Inc., Helix Biotech, Polymun Scientific Immunbiologische Forschung GmbH, and Other Prominent Players

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs) Snapshot

Chapter 4. Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs) Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

4.9. Clinical Trial/Pipeline Analysis

4.10. Application of mRNA Beyond COVID 19 Vaccine

Chapter 5. Market Segmentation 1: By Products, Estimates & Trend Analysis

5.1. By Products, & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Products:

5.2.1. mRNA

5.2.2. Plasmid DNA (pDNA)

5.2.3. siRNA

5.2.4. saRNA

5.2.5. microRNA

5.2.6. Other Products

Chapter 6. Market Segmentation 2: By End-Users Estimates & Trend Analysis

6.1. By End-Users & Market Share, 2020 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By End-Users:

6.2.1. Pharmaceutical Companies

6.2.2. Academic Research Institute

6.2.3. Diagnostic Laboratories

Chapter 7. Market Segmentation 3: By Scale of Operation Estimates & Trend Analysis

7.1. By Scale of Operation & Market Share, 2020& 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Scale of Operation:

7.2.1. Preclinical

7.2.2. Clinical

7.2.3. Commercial

Chapter 8. Lipid Nanoparticles (LNPs) CDMO Market Segmentation 5: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts By Products, 2019-2030

8.1.2. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts By End-Users, 2019-2030

8.1.3. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts By Scale of Operation, 2019-2030

8.1.4. North America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) estimates and forecasts by country, 2019-2030

8.2. Europe

8.2.1. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, 2019-2030

8.2.2. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, 2019-2030

8.2.3. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, 2019-2030

8.2.4. Europe Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2019-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, 2019-2030

8.3.2. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, 2019-2030

8.3.3. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, 2019-2030

8.3.4. Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2019-2030

8.4. Latin America

8.4.1. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, (US$ Million) 2019-2030

8.4.2. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, (US$ Million) 2019-2030

8.4.3. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2019-2030

8.4.4. Latin America Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2019-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Products, (US$ Million) 2019-2030

8.5.2. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By End-Users, (US$ Million) 2019-2030

8.5.3. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2019-2030

8.5.4. Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market revenue (US$ Million) by country, 2019-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Corden Pharma GmbH

9.2.2. eTheRNA

9.2.3. Curapath (Polypeptide Therapeutic Solutions (PTS))

9.2.4. FUJIFILM Corporation

9.2.5. ST Pharm Co Ltd

9.2.6. Exelead (Merck KGaA)

9.2.7. Avanti Polar Lipids, Inc. (Croda International Plc.)

9.2.8. Emergent CDMO

9.2.9. Esco Aster Pte Ltd

9.2.10. Vernal Biosciences

9.2.11. Arranta Bio

9.2.12. Ardena Holding NV

9.2.13. Curia Global, Inc.

9.2.14. Helix Biotech

9.2.15. Phosphorex Inc

9.2.16. Polymun Scientific Immunbiologische Forschung GmbH

9.2.17. Other Prominent Players

Global Lipid Nanoparticles (LNPs) CDMO Market, by Product, 2020-2030 (Value US$ Mn)

  • mRNA
  • Plasmid DNA (pDNA)
  • siRNA
  • saRNA
  • microRNA
  • Others

Global Lipid Nanoparticles (LNPs) CDMO Market, by Scale of Operation, 2020-2030 (Value US$ Mn)

  • Preclinical Scale Operations
  • Clinical Scale Operations
  • Commercial Scale Operations

Global Lipid Nanoparticles (LNPs) CDMO Market, by By End-Users, 2020-2030 (Value US$ Mn)

  • Pharmaceutical Companies
  • Academic Research Institute
  • Diagnostic Laboratories

Global Lipid Nanoparticles (LNPs) CDMO Market, by Region, 2020-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Lipid Nanoparticles (LNPs) CDMO Market, by Country, 2020-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Lipid Nanoparticles (LNPs) CDMO Market, by Country, 2020-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Lipid Nanoparticles (LNPs) CDMO Market, by Country, 2020-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Lipid Nanoparticles (LNPs) CDMO Market, by Country, 2020-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Lipid Nanoparticles (LNPs) CDMO Market, by Country, 2020-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Landscape

  • Company Overview
  • Financial Performance
  • Key Development
  • Latest Strategic Developments

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

 

Need Complete Report ?
Our Clients